Minimally Invasive Treatment for Benign Prostatic Hyperplasia: Economic Evaluation from a Standardized Hospital Case Costing System
- 75 Downloads
Minimally invasive alternatives to transurethral resection of the prostate (TURP) such as prostate arterial embolization (PAE) and photoselective vaporization of the prostate (PVP) are being explored as adjuncts in the care of patients with benign prostatic hyperplasia. However, there are conflicting reports of the costs of these procedures. The purpose of this study was to compare the direct and indirect hospital costs of TURP, PAE and PVP.
Materials and Methods
A chart review was performed in patients who underwent TURP, PVP and PAE from April 2015 to March 2017. All hospital costs were collected in accordance with the Ontario Case Costing Initiative, a standardized medical case costing system. Costs were characterized as direct or indirect and fixed or variable. Probabilistic sensitivity analysis was conducted to study cost uncertainty.
During the study period, a total of 209 men underwent TURP, 28 PVP and 21 PAE. Mean age (years) was as follows: TURP 71.43; PVP 73.66; PAE 70.77 (p = 0.366). Mean length of stay (days) was as follows: TURP 1.63; PVP 1.55; PAE 1 (p = 0.076). Total costs of the PAE group ($3829, SD $1582) were less than both PVP ($5719, SD $1515) and TURP groups ($5034, SD $1997, p < 0.001). There was no significant difference in direct costs between the groups. Monte Carlo simulation demonstrated that PAE was the least costly alternative majority of the time.
The total hospital costs of PAE at our institution are significantly lower than those of PVP and TURP.
KeywordsBPH Cost Prostate artery embolization (PAE) Photoselective vaporization of the prostate (PVP) TURP
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
For this type of study, formal consent is not required.
This study has obtained IRB approval from research ethics board (University Health Network), and the need for informed consent was waived.
Consent for Publication
For this type of study, consent for publication is not required.
- 1.Getzenberg RH, Kulkarni P. Etiology and pathogenesis. In: Kaplan SA, McVary KT, editors. Male lower urinary tract symptoms and benign prostatic hyperplasia. Chichester: Wiley; 2014. p. 218.Google Scholar
- 2.McConnell JD, Barry MJ, Bruskewitz RC. Benign prostatic hyperplasia: diagnosis and treatment. Agency for health care policy and research. Clin Pract Guidel Quick Ref Guide Clin. 1994;8:1–17.Google Scholar
- 12.Capitan C, Blazquez C, Martin MD, et al. GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: a randomized clinical trial with 2-year follow-up. Eur Urol. 2011;60:734–9.CrossRefGoogle Scholar
- 15.Whelan A. Prospective trial of GreenLight PVP (HPS120) versus transurethral resection of the prostate in the treatment of lower urinary tract symptoms in Ontario, Canada; 2013.Google Scholar
- 17.Carnevale FC, Antunes AA, da Motta Leal Filho JM, de Oliveira Cerri LM, Baroni RH, Marcelino AS, Freire GC, Moreira AM, Srougi M, Cerri GG. Prostatic artery embolization as a primary treatment for benign prostatic hyperplasia: preliminary results in two patients. Cardiovasc Intervent Radiol. 2010;33(2):355–61.CrossRefGoogle Scholar
- 21.Guidance document for the costing of health care resources in the Canadian setting, 2nd edn. Ottawa: CADTH; 2016.Google Scholar
- 22.Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;57:289–300.Google Scholar
- 23.Bank of Canada. Annual exchange rates. Bank of Canada, 2017. https://www.bankofcanada.ca/rates/exchange/annual-average-exchange-rates/. Accessed 7 July 2018.
- 26.Whitty JA, Crosland P, Hewson K, Narula R, Nathan TR, Campbell PA, Keller A, Scuffham PA. A cost-minimisation analysis comparing photoselective vaporisation (PVP) and transurethral resection of the prostate (TURP) for the management of symptomatic benign prostatic hyperplasia (BPH) in Queensland, Australia. BJU Int. 2014;113(Suppl 2):21–8.CrossRefGoogle Scholar